New: Introducing the Finviz Crypto Map

Tonix Pharmaceuticals Holding Corp.

Contributing Author

Recent Articles by Tonix Pharmaceuticals Holding Corp.

Jul-21	Tonix Pharmaceuticals Announces the Launch of the "Move Fibro Forward" Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia TNXP GlobeNewswire
Jul-10	Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025 TNXP GlobeNewswire
Jul-09	Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine TNXP GlobeNewswire
Jul-07	Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025 TNXP GlobeNewswire
Jul-02	Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models TNXP GlobeNewswire
Jun-30	Tonix Pharmaceuticals Announces Inclusion in the Russell 3000 and Russell 2000 Indexes TNXP GlobeNewswire
Jun-16	Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 TNXP GlobeNewswire
Jun-13	Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James "Jim" Hunter, to Board of Directors TNXP GlobeNewswire
Jun-10	Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention TNXP GlobeNewswire
Jun-05	Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025 TNXP GlobeNewswire
May-22	Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase TNXP GlobeNewswire
May-21	Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction TNXP GlobeNewswire
May-14	Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations TNXP GlobeNewswire
May-12	Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights TNXP GlobeNewswire

Affiliate • Advertise • Theme Settings • Contact • Blog • Help • Privacy • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.